Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ID-LV305 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intradermal (ID-LV305), Intravenous (pembrolizumab)
01
Overview
ID-LV305 + pembrolizumab is an investigational combination immunotherapy consisting of two components: ID-LV305, an engineered lentiviral vector vaccine targeting NY-ESO-1 antigen, and pembrolizumab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). ID-LV305 is designed to stimulate dendritic cells to generate a specific T-cell immune response against NY-ESO-1-expressing tumors, while pembrolizumab blocks the PD-1 pathway to prevent tumor-mediated immune evasion. This combination aims to enhance anti-tumor immunity in cancers expressing NY-ESO-1, such as melanoma, sarcoma, ovarian cancer, or small cell lung cancer. Clinical studies have evaluated the safety and immune response of this regimen in patients with advanced malignancies, particularly those unresponsive to prior anti-PD-1 therapies[3][5][6].
- Other names
- ID-LV305 + pembrolizumab
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)PDCD1 (Programmed cell death protein 1 receptor)CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)
Beyond the preview
Go deeper on ID-LV305 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ID-LV305 + pembrolizumab.